Recent Updates
Recently added Catalysts

Esophageal Squamous Cell Carcinoma: one US-listed biotech with a clinical-stage programme

OncologyUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$3.5Buniverse median $1.20B
Allocated capital$1.2B$3.5B competing
Phase 3 or filed00 mid, 1 early
Pure plays0this indication only
Capital rank134/299crowding rank 149

Esophageal Squamous Cell Carcinoma is uncontested. IDEAYA Biosciences (IDYA) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with IDE034 in phase 1.

There is no public comparable to price it against. IDYA spreads its $3.5B market cap across 3 indications, so $1.2B of it is allocated here.

Nothing here has reached Phase 3: 0 programmes in mid stage and 1 in early stage, so the field is still several years from a first approval.

$1.2B of allocated capital sits in Esophageal Squamous Cell Carcinoma, ranking it 134th of 299 indications by the money committed to it.

Companies developing drugs for Esophageal Squamous Cell Carcinoma 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
IDYAIDEAYA BiosciencesIDE034Phase 11$3.5BNo3 1 Oct 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why Esophageal Squamous Cell Carcinoma counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Esophageal Squamous Cell Carcinoma has one competitor and a median of $3.5B.

Oncology

Oncology holds $187B of the map's capital, 27.8% of the total, spread across 119 indications and 103 companies. 34 of those indications have more than one company competing.

See every Oncology indication on the map

Related indications in Oncology

Small Cell Lung Cancer Extensive Stage1 company · $1.1B · median $16.1BUncontestedHER2 Positive Metastatic Breast Cancer1 company · $1.1B · median $16.1BUncontestedGastroesophageal Junction Adenocarcinoma1 company · $1.1B · median $16.1BUncontestedCNS Lymphoma1 company · $1.1B · median $16.1BUncontestedDiffuse Midline Glioma1 company · $1.1B · median $16.1BUncontestedH3 K27M Mutant Glioma1 company · $1.1B · median $16.1BUncontestedMyelofibrosis3 companies · $1.3B · median $1.8BConcentrated betEpithelial Ovarian Carcinoma1 company · $1.3B · median $2.6BUncontested

Esophageal Squamous Cell Carcinoma pipeline questions

Which biotech companies are developing drugs for Esophageal Squamous Cell Carcinoma?

IDEAYA Biosciences (IDYA, IDE034, Phase 1). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in Esophageal Squamous Cell Carcinoma.

How advanced is the Esophageal Squamous Cell Carcinoma pipeline?

Of the 1 clinical-stage programme in Esophageal Squamous Cell Carcinoma, 0 are in Phase 3 or filed, 0 are in mid-stage development and 1 is in early-stage development.

Is anyone else developing a drug for Esophageal Squamous Cell Carcinoma?

No. IDYA is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in Esophageal Squamous Cell Carcinoma, which is why the indication is classified as uncontested.

When is the next Esophageal Squamous Cell Carcinoma catalyst?

The next dated catalyst in Esophageal Squamous Cell Carcinoma is IDYA on 1 Oct 2026. 1 dated event across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map